PCC Weekly

depression

Brief Report

Psilocybin Can Diminish Depression

Prim Care Companion CNS Disord 2020;22(5):19br02580

Original Research

A Randomized Controlled Feasibility Trial of Reminder-Focused Positive Psychiatry in Adolescents With Comorbid Attention-Deficit/Hyperactivity Disorder and Posttraumatic Stress Disorder [Free PDF]

Prim Care Companion CNS Disord 2020;22(5):19m02579

Case Report

Escitalopram-Induced Hair Loss

Prim Care Companion CNS Disord 2020;22(4):19l02496

Original Research

Oral Administration of S-Adenosylmethionine (SAMe) and Lactobacillus Plantarum HEAL9 Improves the Mild-To-Moderate Symptoms of Depression: A Randomized, Double-Blind, Placebo-Controlled Study [Free PDF]

Prim Care Companion CNS Disord 2020;22(4):19m02578

Case Report

Three Months of Treatment With Esketamine: Effects on Depression, Insomnia, and Weight

Prim Care Companion CNS Disord 2020;22(4):19l02555

Original Research

Feasibility Study of Stress Management and Resiliency Training (SMART) in Patients With Major Depressive Disorder [Free PDF]

Prim Care Companion CNS Disord 2020;22(3):19m02556

Original Research

A Longitudinal Comparison Between Depressed Patients Receiving Electroconvulsive Therapy and Healthy Controls on Specific Memory Functions [Free PDF]

Prim Care Companion CNS Disord 2020;22(3):19m02547

Case Report

Autoimmune Encephalitis With Elevated N-Type Calcium Channel Antibodies Presenting as Psychotic Depression

Prim Care Companion CNS Disord 2020;22(3):19l02521

Letter to the Editor

Effectiveness and Safety of Intravenous Ketamine for Severely Depressed Patients Unable to Receive Electroconvulsive Therapy Due to Medical Risks

Prim Care Companion CNS Disord 2020;22(3):19l02535

Review Article | Earn Credit

Psychiatric Prodrome in Anti-NMDAR–Associated Encephalopathy: Clinical and Pathophysiologic Considerations

Prim Care Companion CNS Disord 2020;22(3):19r02563

1 - 10 Next